Today, we are pleased to announce a more formalized organizational structure for 46brooklyn. This month, we received word from the IRS that 46brooklyn Research is now officially recognized as a 501(c)(3) Public Charity. As a tax-exempt non-profit organization, our main goal remains the same: to improve the accessibility and usability of U.S. drug pricing data. Our hope is that better awareness and education will help improve the accountability of our prescription drug supply chain and, in time, lead to the much-needed simplification of how drugs are priced.
With two months of solid data so far in 2019, according to CMS data, brand drug list prices appear to be largely under control when compared to previous years. While the data does not reflect true net costs, these are noteworthy trends regardless, and signs of the erosion of the much-maligned drug pricing “gross-to-net-bubble.” Check out this update for a breakdown of the price increases, as well as an update on the peculiar case of generic Prilosec spending.
The start of each new year brings a lot of “new-ness,” including a new round of price increases on brand-name drugs. This year has been no exception, and the media has been all over the subject. Unfortunately, we’ve found it difficult to figure out the “so what?” behind all of these price increases. On one hand, we are being told that the pharmaceutical manufacturers are back to “business as usual,” while on the other we are being told that the number of price increases are down meaningfully from last year. Which one is it? This felt like an opportunity to inject a healthy dose of facts into this discussion. So we set out to build a dashboard, 46brooklyn’s Brand Drug Price Change Box Score, that lets you visualize all brand-name manufacturer list price changes that are publicly-reported each week, drill down to the manufacturer and drug level, strength level, and compare and contrast different periods.
After Bloomberg put drug price markups on the map, we decided a deeper dive into markups was warranted to see which drugs were getting overinflated and which drugs were not. To sort things out, we built a new visualization dashboard to compare drug markups between state Medicaid programs. We call our creation the “Medicaid Markup Universe.” In this new visualization tool, we found a disturbingly large difference in drug markups across generic drugs in state Medicaid managed care programs, resulting in a slew of warped incentives that pressure supply chain members to value certain medications over others, and thus, certain patients over others. Check out our newest visualization tool and read our latest drug pricing report.
On August 20, 2018, the U.S. Department of Health and Human Services (HHS) released an analysis of the accomplishments that the Trump administration has achieved in the first 100 days since the release of the President’s American Patients First Blueprint to lower prescription drug prices. The HHS Report on 100 Days of Action on the American Patient First Blueprint provides some interesting insight into the Trump administration’s progress on delivering on their promise of lower drug prices. While there is a lot that needs deciphering, HHS made two very significant claims in this report. They assert that over the first 100 days since the Blueprint's release there have been significantly less brand-drug price increases, and significantly more generic and brand price decreases. After some careful number-crunching and analysis, we can now tell you where we believe the administration seems to be making headway and where things still seem incomplete. More importantly, we hope we can provide some better clarity into whether or not any current actions have directly impacted lower drug costs. Check out our newest research that shows what really happened to drug prices in the first 100 days since the release of the White House blueprint.